218 related articles for article (PubMed ID: 20140939)
1. Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma.
Sommer J; Itani DM; Homlar KC; Keedy VL; Halpern JL; Holt GE; Schwartz HS; Coffin CM; Kelley MJ; Cates JM
J Pathol; 2010 Apr; 220(5):608-17. PubMed ID: 20140939
[TBL] [Abstract][Full Text] [Related]
2. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM
J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079
[TBL] [Abstract][Full Text] [Related]
3. Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP- malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis.
Chen ZH; Olopade OI; Savarese TM
Mol Pharmacol; 1997 Nov; 52(5):903-11. PubMed ID: 9351982
[TBL] [Abstract][Full Text] [Related]
4. Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma.
Chapel DB; Dubuc AM; Hornick JL; Sholl LM
Histopathology; 2021 Jun; 78(7):1032-1042. PubMed ID: 33387364
[TBL] [Abstract][Full Text] [Related]
5. The transcriptional factors CDX2 and FOXA1 in chordomas.
Dridi M; Boutonnat J; Dumollard JM; Peoc'h M; Karpathiou G
Pathol Res Pract; 2020 Nov; 216(11):153160. PubMed ID: 32911347
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase receptor expression in chordomas: phosphorylated AKT correlates inversely with outcome.
de Castro CV; Guimaraes G; Aguiar S; Lopes A; Baiocchi G; da Cunha IW; Campos AH; Soares FA; Begnami MD
Hum Pathol; 2013 Sep; 44(9):1747-55. PubMed ID: 23618355
[TBL] [Abstract][Full Text] [Related]
7. MTAP is an independent prognosis marker and the concordant loss of MTAP and p16 expression predicts short survival in non-small cell lung cancer patients.
Su CY; Chang YC; Chan YC; Lin TC; Huang MS; Yang CJ; Hsiao M
Eur J Surg Oncol; 2014 Sep; 40(9):1143-50. PubMed ID: 24969958
[TBL] [Abstract][Full Text] [Related]
8. Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma.
García-Castellano JM; Villanueva A; Healey JH; Sowers R; Cordon-Cardo C; Huvos A; Bertino JR; Meyers P; Gorlick R
Clin Cancer Res; 2002 Mar; 8(3):782-7. PubMed ID: 11895909
[TBL] [Abstract][Full Text] [Related]
9. Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordoma.
Cottone L; Eden N; Usher I; Lombard P; Ye H; Ligammari L; Lindsay D; Brandner S; Pižem J; Pillay N; Tirabosco R; Amary F; Flanagan AM
J Pathol Clin Res; 2020 Apr; 6(2):113-123. PubMed ID: 31916407
[TBL] [Abstract][Full Text] [Related]
10. Does insulin-like growth factor 1 receptor (IGF-1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study.
Scheipl S; Froehlich EV; Leithner A; Beham A; Quehenberger F; Mokry M; Stammberger H; Varga PP; Lazáry A; Windhager R; Gattenloehner S; Liegl B
Histopathology; 2012 May; 60(6):999-1003. PubMed ID: 22372631
[TBL] [Abstract][Full Text] [Related]
11. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
Berg KB; Dacic S; Miller C; Cheung S; Churg A
Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma.
Fasig JH; Dupont WD; LaFleur BJ; Olson SJ; Cates JM
Neuropathol Appl Neurobiol; 2008 Feb; 34(1):95-104. PubMed ID: 17973908
[TBL] [Abstract][Full Text] [Related]
13. Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications.
Powell EL; Leoni LM; Canto MI; Forastiere AA; Iocobuzio-Donahue CA; Wang JS; Maitra A; Montgomery E
Am J Surg Pathol; 2005 Nov; 29(11):1497-504. PubMed ID: 16224217
[TBL] [Abstract][Full Text] [Related]
14. Expression of E-cadherin in chordomas: diagnostic marker and possible role of tumor cell affinity.
Mori K; Chano T; Kushima R; Hukuda S; Okabe H
Virchows Arch; 2002 Feb; 440(2):123-127. PubMed ID: 11964040
[TBL] [Abstract][Full Text] [Related]
15. Loss of MTAP expression is a negative prognostic marker in Ewing sarcoma family of tumors.
Abrahao-Machado LF; Antunes B; Filippi RZ; Volc S; Boldrini E; Menezes WP; Reis RM; de Camargo OP
Biomark Med; 2018 Jan; 12(1):35-44. PubMed ID: 29243509
[TBL] [Abstract][Full Text] [Related]
16. Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray-based comparative analysis.
Oakley GJ; Fuhrer K; Seethala RR
Mod Pathol; 2008 Dec; 21(12):1461-9. PubMed ID: 18820665
[TBL] [Abstract][Full Text] [Related]
17. Expression of vascular endothelial growth factor receptor 2 (VEGFR-2), inducible nitric oxide synthase (iNOS), and Ki-M1P in skull base chordoma: a series of 145 tumors.
Akhavan-Sigari R; Gaab MR; Rohde V; Brandis A; Tezval H; Abili M; von Eckardstein K; Ostertag H
Neurosurg Rev; 2014 Jan; 37(1):79-88. PubMed ID: 23999886
[TBL] [Abstract][Full Text] [Related]
18. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors.
Naka T; Iwamoto Y; Shinohara N; Ushijima M; Chuman H; Tsuneyoshi M
Mod Pathol; 1997 Aug; 10(8):832-8. PubMed ID: 9267827
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
Berg KB; Churg AM; Cheung S; Dacic S
Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
[TBL] [Abstract][Full Text] [Related]
20. Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers.
Karikari CA; Mullendore M; Eshleman JR; Argani P; Leoni LM; Chattopadhyay S; Hidalgo M; Maitra A
Mol Cancer Ther; 2005 Dec; 4(12):1860-6. PubMed ID: 16373701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
